AZNCF News and Press, AstraZeneca Plc From 04/13/20

Sangamo Closes Gene Collaboration with Biogen Sangamo Therapeutics ( SGMO ) reported that it has finalized its sale of stock to Biogen ( BIIB ), leading to the formal initiation of its global licensing collaboration with latter. The collaboration pertains to gene regulation therapies in ...

New York City, NY:March 25, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cystic Fibrosis (CF) Therapeutics Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the re...

Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...

Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates Esperion Therapeutics ( ESPR ) is on the verge of a major catalyst as the company awaits the FDA decision for bempedoic acid as a treatment for increased LDL cholesterol. The agency is scheduled to deliver its...

Veeva ( VEEV ) has been a leader of cloud-based compliance and software solutions for the growing life sciences industry. The business is comprised of two segments: Veeva Commercial Cloud and Veeva Vault. Commercial Cloud is Veeva's flagship product and provides features to customers, inc...

AstraZeneca PLC (AZN) Q4 2019 Earnings Conference Call February 14, 2020 7:00 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President, Oncology Ruud Dobber – Executive Vice President, BioPharmaceutical Bu...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2019 Q4 earnings Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher’s 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management’s regulatory 13F Form filed on 02/12/2020. Please visit our Tracking Kenneth Fisher's Fis...

As we closed out 2019, I featured the resurgence of some big pharma names ( Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield ) an d believe they have further room to run in 2020 and beyond. Previously featuring BMY, another name I continue to own is AstraZeneca PLC ...

Quick Take Revolution Medicines ( RVMD ) intends to raise $150 million from the sale of its common stock, according to an amended registration statement. The company is in Phase 1/2 trials for the development of treatments for various types of cancers. RVMD has produced promising early r...